A VISION OF GIVING BACK
It is fundamental for DLIMI that insights generated in our research and projects become part of the open, shared body of knowledge on which the pharmaceutical and healthcare sectors advance. On this page you find examples of such projects.
Our research-based projects are often carried out in collaboration with authorities, universities and other research organizations. This broadens our understanding of the societal context of pharmaceuticals and sharpens our knowledge of new scientific methodologies and technologies. All in all, through our private-public collaboration DLIMI helps create those synergies that result in better care for patients.
AUTHORISED ACCESS TO THE “FORSKERMASKINE”
DLIMI is authorized by Statistics Denmark and the Danish Health Data Authority to access data on the “Forskermaskine”. This means that our research activities, knowledge of data security and registry data have been officially approved. Consequently, we are able to gain access to microdata for the projects we solve.
RWE ANALYSIS OF COST OF MEDICINE FOR ADULTS WITH ADHD
DLIMI conducted a real-world data analysis of adults in stable treatment with ADHD medicine in order to explore the characteristics and cost of medicine for adults with ADHD.
Nordic research collaboration – IBD study
DLIMI participated in a Nordic collaboration coordinated by Oslo University with the purpose of mapping treatment of patients suffering from inflammatory bowel disease with biological drugs.
long-term insulin treatment of Type 1 and 2 diabetics
DLIMI analyzed statistical data from the Danish Health Data Authority to map T1D and T2D treatment with basal insulin: The types of drugs prescribed for new patients, and the number of changes in drugs.
modelling COST EFFICIENCY OF BIOLOGICAL TREATMENT
DLIMI participated as supervisors for a thesis (University of Copenhagen, Department of Public Health) to model cost-effectiveness of biological treatment of inflammatory bowel diseases.
chronic obstructive Pulmonary Disease ANALYSIS
On behalf of GSK, DLIMI conducted a real-world data analysis of COPD on different aspects of treatment and the patient journey in Denmark. The most frequent treatment was found to be triple therapy.
SIGN UP FOR OUR NEWSLETTER
Get the latest news, instant insights, cases, whitepapers and stay up to date.
We promise only to send relevant and exiting news.